Promising initial clinical trial results
have led Aduro to initiate an approximate 300-patient Phase 2b ECLIPSE trial of its lead product, a combination of the engineered bacterium CRS-207 and GVAX Pancreas, in patients with metastatic pancreatic cancer. CRS-207 is the first candidate to emerge from Aduro’s proprietary LADD platform. Read More.
Aduro’s novel technology
harnesses the immune system by activating both innate and adaptive immunity in patients. This proprietary therapy – alone and in combination with other treatments – is engineered to generate a potent and long-lasting response to specific cancers. Read More.